Dan Schneider & Photocure

Dan Schneider: Dan Schneider, CEO of Photocure, commented on the results and strategic progress, highlighting the acquisition of Vesica Health and FDA reclassification as key catalysts.

Photocure: Photocure reported Q2 2026 results with revenue growth, raised guidance, and advanced strategic initiatives including the acquisition of Vesica Health and collaboration with Artera. The company is well-positioned for future growth.

Dan Schneider: Dan Schneider, President and CEO of Photocure, highlighted Photocure's expanded vision to develop complementary precision diagnostic solutions and accelerate personalized care.

Photocure: Photocure is a key partner in this research initiative, providing its BLC registry data and expertise in bladder cancer diagnostics to develop and validate the ArteraAI Bladder Test. This collaboration enhances Photocure's position in precision medicine.

Dan Schneider: Dan Schneider, CEO of Photocure, publicly welcomed the FDA's proposal, highlighting its importance for the company and the bladder cancer community.

Photocure: Photocure is the primary beneficiary, as the reclassification could expand the U.S. market for its Cysview product and related equipment, potentially increasing sales and market share.

Dan Schneider: Dan Schneider is the President and CEO of Photocure, mentioned as a contact for the announcement.

Photocure: Photocure announced the study publication, which supports the cost-effectiveness of its product Hexvix/Cysview, potentially strengthening its market position.

Photocure: Photocure reported strong Q1 2026 revenues and adjusted EBITDA, with significant milestone payments for Cevira approvals. The company expects continued product revenue growth and EBITDA margin expansion, driven by increased adoption of blue-light cystoscopy and strategic partnerships.